Company: PFSA
Filing Date: 2025-04-03
Form Type: S-4/A
Source: 0001213900-25-028544
Chunk: 62

Company: Profusa, Inc.
Filing Date: 2025-04-03
Form: S-4/A
Chunk 62
---
 March21, 2025, NorthView’s stockholders redeemed 9.1% of the total outstanding shares. The aggregate of 18,820,439 public shares redeemed in connection with the Extension represented approximately 77.9% of the total NorthView shares of common stock outstanding following NorthView’s IPO and approximately 99.2% of the public shares previously outstanding. As of March21, 2025, NorthView had 154,561 public shares of NorthView Common Stock outstanding, and held approximately $1.9 million in the Trust Account. As of [•], the record date, the closing price of the NorthView Common Stock, the NorthView Rights, and the NorthView Warrants were $[•], $[•] and $[•] per security, respectively. Upon consummation of the Business Combination, NorthView’s common stock will be listed on Nasdaq under the symbol “PFSA,” and its warrants will be listed on Nasdaq under the symbol “PFSAW.” The mailing address of NorthView’s principal executive offices is 207 West 25 thSt., 9 thfloor, New York, NY 10001, and its telephone number is (212) 494 -9022. Merger Sub NV Profusa Merger Sub Inc. is a Delaware corporation and a direct wholly owned subsidiary of NorthView. Merger Sub was incorporated on October 4, 2022. Merger Sub was formed solely in contemplation of the Business Combination, has not commenced any operations, has only nominal assets and has no liabilities or contingent liabilities, nor any outstanding commitments other than in connection with the Business Combination. Profusa Profusa is a California corporation incorporated on February 2, 2009. Profusa is a digital health technology company based in Berkeley, CA, that has developed a real time, consumer -friendlyplatform that is designed to measure an individual’s biochemistry, be easy to use, be cost -effective, and provide the necessary data to manage chronic disease and health and wellness decisions to improve health outcomes for a large population of potential users. 2 Profusa currently has two products in development, Lumee Oxygen and Lumee Glucose, both of which rely on implantable hydrogel sensors that are permanently injected into subcutaneous tissue and are subject to FDA regulation as class III medical devices. Lumee Oxygen has received CE mark approval in the European Union but has not yet been approved by the FDA for medical use in the US. Lumee Oxygen is designed